MetaCap

DiaMedica Therapeutics (DMAC) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 119.7% versus a gain of 8.1%. Over five years, DMAC leads with a +118.8% price change compared with -52.0% for STTK. Shattuck Labs is the larger company by market cap ($454.2 million vs $445.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DMAC+8.13%STTK+119.70%
+313%+133%-47%
Nov 21, 20251 yearNov 20, 2026
DMAC+115.97%STTK-52.55%
+158%+27%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DMAC versus STTK key metrics
MetricDMACSTTK
Share price$8.25$4.46
Market cap$445.15M$454.22M
1-day change+2.87%-1.98%
YTD return+3.64%+22.19%
1-year return+8.13%+119.70%
5-year return+118.83%-51.99%
EPS (TTM)$-0.75$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.00M
Revenue growth (YoY)—-82.52%
Net income (latest FY)$-32.77M$-48.81M
Operating margin—-5150.80%
Net margin—-4880.90%
52-week high$11.00$8.33
52-week low$5.25$1.93
Distance from 52-week high-25.00%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+96.97%+245.29%
Average volume210.46K1.20M
Shares outstanding53.96M101.84M
Employees3540
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed DMAC by 111.6 percentage points over the past year.

About DiaMedica Therapeutics

DMAC stock →

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

DMAC vs STTK FAQ

Which is bigger, DiaMedica Therapeutics or Shattuck Labs?

Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $445.15M for DiaMedica Therapeutics (DMAC).

Which stock has performed better over the past year, DMAC or STTK?

STTK returned +119.70% over the past 12 months, compared with +8.13% for DMAC (price return, excluding dividends). Past performance does not predict future results.

Are DiaMedica Therapeutics and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons